Table 2.

Comparative effectiveness analysis of DPP4i and dapagliflozin on secondary outcomes

	Outcome	DPP4i				Dapagliflozin				ETD (SE)	p
		N	Baseline	Follow-up	Change	N	Baseline	Follow-up	Change
ITT
Observed	HbA1c	977	8.0 ± 0.8	7.4 ± 0.9	− 0.6 ± 1.0^	445	8.9 ± 1.2	8.0 ± 1.2	− 0.9 ± 1.2^	0.11 (0.06)	0.07
	Weight	821	75.6 ± 14.2	74.7 ± 13.9	− 1.0 ± 3.3^	401	86.1 ± 15.5	83.5 ± 15.8	− 2.6 ± 6.5^	− 1.20 (0.34)	0.001
	SBP	634	139.6 ± 19.0	137.7 ± 17.6	− 1.9 ± 19.3*	315	144.6 ± 20.2	140.2 ± 18.1	− 4.5 ± 20.8^	− 2.73 (1.37)	0.046
IPTW	HbA1c	977	8.3 ± 1.4	7.5 ± 1.1	− 0.8 ± 1.5	445	8.3 ± 1.9	7.6 ± 1.8	− 0.7 ± 1.8	0.12 (0.07)	0.079
	Weight	821	78.2 ± 18.0	77.2 ± 17.5	− 1.1 ± 4.0	401	79.8 ± 24.9	77.9 ± 28.3	− 2.0 ± 16.9	− 0.88 (0.45)	0.053
	SBP	634	141.3 ± 23.3	139.2 ± 22.1	− 2.1 ± 23.5	315	139.7 ± 32.1	136.0 ± 28.2	− 3.7 ± 33.8	− 1.53 (1.47)	0.30
AT
Observed	HbA1c	770	8.0 ± 0.8	7.3 ± 0.8	− 0.7 ± 1.0^	320	9.0 ± 1.2	7.9 ± 1.1	− 1.1 ± 1.3^	0.12 (0.07)	0.08
	Weight	649	75.8 ± 14.0	74.9 ± 13.8	− 0.9 ± 3.1^	288	86.0 ± 15.8	83.1 ± 16.4	− 2.9 ± 7.2^	− 1.73 (0.42)	< .0001
	SBP	489	139.6 ± 18.9	137.8 ± 17.7	− 1.9 ± 19.4*	227	143.2 ± 19.7	139.3 ± 18.4	− 4.0 ± 20.4*	− 3.46 (1.63)	0.034
IPTW	HbA1c	770	8.4 ± 1.5	7.4 ± 1.1	− 1.0 ± 1.5	320	8.3 ± 2.0	7.5 ± 1.8	− 0.8 ± 2.0	0.14 (0.08)	0.062
	Weight	649	77.7 ± 16.9	76.7 ± 16.6	− 1.0 ± 3.8	288	79.9 ± 25.3	77.4 ± 29.4	− 2.5 ± 17.8	− 1.49 (0.50)	0.003
	SBP	489	141.3 ± 23.0	139.0 ± 21.7	− 2.3 ± 23.7	227	138.0 ± 34.2	134.8 ± 28.3	− 3.2 ± 35.1	− 0.87 (1.57)	0.581

For each comparison and outcome, we report the number of patients, the values (mean and SD) at baseline and follow-up, the change from baseline, and the estimated treatment difference (ETD) with its standard error (SE), along with the respective p values. *p < 0.05 versus baseline; ^p < 0.001 versus baseline

SBP systolic blood pressure, FPG fasting plasma glucose, ITT intention to treat, AT as treated. The pooled ATD from the ten imputed dataset are presented